PHARMA Stock Overview
An investment holding company, operates as an integrated healthcare service provider in Malaysia, Indonesia, and internationally. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 3/6 |
| Financial Health | 1/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
Pharmaniaga Berhad Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | RM 0.24 |
| 52 Week High | RM 0.47 |
| 52 Week Low | RM 0.20 |
| Beta | 1.35 |
| 1 Month Change | 4.35% |
| 3 Month Change | -27.27% |
| 1 Year Change | -29.41% |
| 3 Year Change | -67.79% |
| 5 Year Change | -28.99% |
| Change since IPO | 107.43% |
Recent News & Updates
Recent updates
There's No Escaping Pharmaniaga Berhad's (KLSE:PHARMA) Muted Revenues
Feb 20
Pharmaniaga Berhad's (KLSE:PHARMA) Shares Bounce 25% But Its Business Still Trails The Industry
Jul 18Why Investors Shouldn't Be Surprised By Pharmaniaga Berhad's (KLSE:PHARMA) Low P/S
May 09Pharmaniaga Berhad (KLSE:PHARMA) Shares Could Be 49% Below Their Intrinsic Value Estimate
Apr 19Insufficient Growth At Pharmaniaga Berhad (KLSE:PHARMA) Hampers Share Price
Oct 03Is There An Opportunity With Pharmaniaga Berhad's (KLSE:PHARMA) 37% Undervaluation?
Jul 19Is It Too Late To Consider Buying Pharmaniaga Berhad (KLSE:PHARMA)?
Feb 18Many Would Be Envious Of Pharmaniaga Berhad's (KLSE:PHARMA) Excellent Returns On Capital
Dec 10Shareholder Returns
| PHARMA | MY Healthcare | MY Market | |
|---|---|---|---|
| 7D | 17.1% | 1.6% | 3.7% |
| 1Y | -29.4% | 13.2% | -6.0% |
Return vs Industry: PHARMA underperformed the MY Healthcare industry which returned 13.2% over the past year.
Return vs Market: PHARMA underperformed the MY Market which returned -6% over the past year.
Price Volatility
| PHARMA volatility | |
|---|---|
| PHARMA Average Weekly Movement | 12.1% |
| Healthcare Industry Average Movement | 5.9% |
| Market Average Movement | 6.4% |
| 10% most volatile stocks in MY Market | 11.8% |
| 10% least volatile stocks in MY Market | 3.3% |
Stable Share Price: PHARMA's share price has been volatile over the past 3 months compared to the MY market.
Volatility Over Time: PHARMA's weekly volatility (12%) has been stable over the past year, but is still higher than 75% of MY stocks.
Community vs My Fair Value
Select a narrative for quick price alerts from the community, or create your own.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1994 | 3,476 | Zulkifli Bin Jafar | www.pharmaniaga.com |
Pharmaniaga Berhad, an investment holding company, operates as an integrated healthcare service provider in Malaysia, Indonesia, and internationally. The company operates through three segments: Logistics and Distribution, Manufacturing, and Indonesia. It is involved in manufacturing, distribution, trading, wholesaling, and marketing pharmaceutical and medical products; supply, trading, and installation of medical and hospital equipment; and trading and wholesaling of consumer products.
Pharmaniaga Berhad Fundamentals Summary
| PHARMA fundamental statistics | |
|---|---|
| Market cap | RM 345.90m |
| Earnings (TTM) | RM 131.82m |
| Revenue (TTM) | RM 3.76b |
2.6x
P/E Ratio0.1x
P/S RatioIs PHARMA overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| PHARMA income statement (TTM) | |
|---|---|
| Revenue | RM 3.76b |
| Cost of Revenue | RM 3.22b |
| Gross Profit | RM 540.49m |
| Other Expenses | RM 408.67m |
| Earnings | RM 131.82m |
Last Reported Earnings
Dec 31, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | 0.091 |
| Gross Margin | 14.38% |
| Net Profit Margin | 3.51% |
| Debt/Equity Ratio | -811.4% |
How did PHARMA perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/04/16 23:14 |
| End of Day Share Price | 2025/04/16 00:00 |
| Earnings | 2024/12/31 |
| Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Pharmaniaga Berhad is covered by 4 analysts. 1 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Hsien Jin Lam | CGS International |
| Yee Low | Hong Leong Investment Bank Berhad |
| Min-Tze Chua | Kenanga Research |